Web Content Display Web Content Display

 

Projects (by (BBMRI.at partners

 

BBMRI.at members and their biobanks are participating in numerous research projects and have received various (local, national, EU) grants

 

Examples of biobanking related research project to which BBMRI.at partners contribute(d):

 

  • BIGPICTURE - Central repository / platform for digital pathology
  • SARS-CoV-2 / COVID-19
  • Instand-NGS4P - integrated and Standardized NGS Workflows for personalised therapy
  • CY-BIOBANK - Center of excellence – biobanking and the Cyprus human genome project
  • EASI-Genomics - European Advanced infraStructure for Innovative Genomics
  • HDHL-INTIMIC Knowledge Platform on Food, Diet, Intestinal Microbiomics and Human Health
  • ERINHA-Advance – Advancing European Research Infrastructure on Highly Pathogenic Agents
  • CONCEPTION
  • EJP RD - European Joint Programme on Rare Diseases
  • EOSC-LIFE
  • Inter-university infrastructure for digital pathology
  • SPIDIA4P - SPIDIA for Personalized Medicine – Standardisation of generic Pre-analytical procedures for Invitro DIAgnostics for Personalized Medicine
  • CODEX4SME - Companion diagnostics expedited for small and medium-sized businesses
  • ADOPT BBMRI-ERIC - ImplementAtion anD OPeration of the gateway for healTh into BBMRI-ERIC
  • CORBEL - Coordinated Research Infrastructures Building Enduring Life-science services
  • RD-CONNECT - An integrated platform connecting registries, biobanks and clinical  bioinformatics for rare disease research
  • BBMRI-LPC - Biobanking and Biomolecular Resources Research Infrastructure – Large Prospective Cohorts
  • B3AFRICA - Bridging Biobanking and Biomedical Research across Europe and Africa

 

 

Project Details

 

BIGPICTURE

European Platform & central repository FOR DIGITAL PATHOLOGY

 

 

The mission of the EU-funded BIGPICTURE project is to establish the first European platform where quality-controlled whole slide imaging (WSI) data are stored. The consortium consists of Europe's largest pathology departments and will work towards an open-source framework for accessing, annotating and mining WSI data using AI algorithms. With access to millions of WSI data, BIGPICTURE envisions AI-based methods that can help clinicians interpret tissue features and perform diagnosis fast, in a high-throughput manner, avoiding human bias or error. More at Cordis.Europe.eu

 

  • Topic: IMI2-2019-18-01 – Central repository of digital pathology slides to support the development of artificial intelligence tools
  • Funded by: EU – Horizon 2020
  • Type of action: IMI2-RIA - Research and Innovation action
  • Start/end: 2021-2027
  • Grant agreement number: 945358
  • Total/max. grant by consortium: €32,319,825
  • Benefit/tasks for BBMRI.at partner: Medical University of Graz: funded / Coordinator
  • Project partners (BBMRI.at partners underlined): Medical University of Graz, Medical University of Vienna, Stichting Katholieke Universiteit, Linkopings Universitet, The Leeds Teaching Hospitals National Health Service Trust, Universitair Medisch Centrum Utrecht, CSC-Tieteen Tieto Tektniikan Keskus OY, Uppsala Universitet, Fraunhofer Gesellschaft zur Förderung der Angewandten Forschung, Haute Ecole Specialisee de Suisse Occidentale, Technische Universiteit Eindhoven, Azienda Ospedaliera per L'Emergenza Cannizzaro, The University of Warwick, Technische Universität München, Institut Pasteur, Universite de Liege, Semmelweis Egyetem, Stichting het Nederlands Kanker Instituut – Antoni van Leeuwenhoek Ziekenhuis, Biobanks and Biomolecular Resources Research Infrastructure Consortium (BBMRI-ERIC), DIN Deutsches Institut für Normung eV, Ostergotlands Lans Landsting, The European Institute for Innovation through Health Data, Helsingin ja Uudenmaan Sairaanhoitopiirin Kuntayhtymä, Philipps Universitaet Marburg, European Society of Pathology Digital Pathology Association inc, GBG Forschungs GmbH, TTopstart BV, Sectra AB, Cytomine, Stichting Lygature, Owkin France, Deciphex Limited, Phit BV, Time.Lex, Novartis Pharma AG, Janssen Pharmaceutica NV, Bayer Aktiengesellschaft, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Pfizer Ltd, F. Hoffmann-La Roche AG, Sanovi-Aventis Recherche & Developpment, Institut de Recherches Internationales Servier Iris, UCB Biopharma SRL
  • Web: www.bigpicture.eu 

 

 

SARS-CoV-2 und COVID-19

 

Several SARS-CoV-2 virus variants were/are cultivated in the BSL-3 laboratory of Med Uni Graz and used for a wide range of functional studies. Issues dealt with include the testing of antiviral drugs, testing of antibodies, testing of nasal sprays and natural substances, development and validation of diagnostics, testing and development of procedures for virus inactivation and reprocessing of protective equipment. For this, virus neutralization assays as well as the latest technologies such as in-situ transcriptome analyzes and organoid and organ cultures are used.

 

  • Start/end: 2020-2024
  • Funded by: Med Uni Graz, Med Uni Wien, Uni-Graz, acib, FFG, MEFO
  • Project partners: (BBMRI.at partners underlined): Medical University of Graz (Diagnostics and Research Institute of Pathology; Diagnostics and Research Institute for Hygiene, Microbiology and Environmental Medicine; Biobank Graz), Medical University of Vienna, Ludwig Boltzmann Institut für Lungengefäßforschung, University Graz, acib, Max Plack Institute for Molecular Genetics Berlin, various companies

 

 

CY-BIOBANK

Center of Excellence – Biobanking and the Cyprus Human Genome Project

 

 

The CY-Biobank project revolves around the upgrading of the existing Biobank of the University of Cyprus, to a Center of Excellence in Biobanking and Biomedical Research, adapting European standards of operation in collaboration with the Advanced Partners. This medical research infrastructure will then serve the foundation for developing the Cyprus human genome project and other genomics/genetics projects for diseases with Mendelian inheritance as well as complex disorders of multifactorial character that impact modern societies. ... more information

 

  • Topic: Towards the Establishment of a Research and Innovation Center of Excellence for Biobanking and Biomedical Research at the University of Cyprus
  • Type of action: CSA - Coordination and Support Actions
  • Funded by: EU Horizon 2020, Teaming 2
  • Start/end: 2019-2026
  • Grant agreement number: 857122
  • Total/max. grant by consortium: €14,999,975.00
  • Benefit/tasks for BBMRI.at partner: Medical University of Graz funded
  • Project partners (BBMRI.at partners underlined): Medical University of Graz (Diagnostics and Research Institute of Pathology; Biobank Graz/International Biobanking Education), University of Cyprus, Biobanks and Biomolecular Resources Research Infrastructure Consortium (BBMRI-ERIC), RTD Talos Limited
  • Web: https://biobank.cy/

 

 

 

Instand-NGS4P

Integrated and Standardized NGS Workflows for Personalised Therapy

 

 

INSTAND-NGS4P is an EU-funded Pre-Commercial Procurement (PCP) project for improving cancer patients' benefit from Next Generation Sequencing (NGS) by developing an integrated and standardized NGS workflow. For this, it will compile information from cancer gene testing, pharmacogenetics testing and e-medication in proper presentation to medical doctors for supporting therapy decision making at bedside widely applicable in health systems. More at Cordis.Europe.eu

  • Topic: SC1-BHC-10-2019 - Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis
  • Funded by: EU – Horizon 2020
  • Type of action: PCP - Pre-Commercial Procurement
  • Start/end:  2020-2025
  • Total/max. grant by consortium: €10.998.128,16
  • Grant agreement number: 874719
  • Benefit/tasks for BBMRI.at partner: Medical University of Graz fund / coordinator
  • Project partners (BBMRI.at partners underlined): Medical University of Graz, University of Florence, ERASMUS University Medical Centre, University of Milano-Bicocca, University Clinics of Schleswig-Holstein, St. Anna Children´s Cancer Research Institute, Centre Leon Bérard, Italian Patient Association (FAVO), European Cancer Patient Coalition, German Institute of Standardisation, Technical University of Munich, University of Ljubljana, University of Manchester, University of Liverpool, Organisation of European Cancer Institutes, University of Helsinki, BioXPedia, International Prevention Research Institute
  • Web: www.instandngs4p.eu

 

 

EASI-Genomics

European Advanced InfraStructure for Innovative Genomics

 

 

The mission of EASI-Genomics is to provide easy and seamless access to cutting-edge DNA sequencing technologies to researchers from academia and industry, within a framework that ensures compliance with ethical and legal requirements, as well as FAIR and secure data management. More at Cordis.Europe.eu

 

  • Topic: H2020, EASI-Genomics, INFRAIA-01-2018-2019 European Advanced InfraStructure for Innovative GenomicsType of action: RIA - Research and Innovation action
  • Funded by: EU Horizon 2020
  • Start/end: 2019-2023
  • Grant agreement number: 824110
  • Total/max. grant by consortium: € 9 991 267
  • Benefit/tasks for BBMRI.at partner: Medical University of Graz funded / coordinates the WP "Innovation, Training and Outreach":
    • Outreach out to the different stakeholders to transfer knowledge and consult with them about their future needs and interests,

    • develop and organise workshops and seminars to train the new generation of users.

    • Creating of a community platform, as a meeting point where users, providers, suppliers, but also funders and policy makers can exchange information about challenges and opportunities.

    • Promotion of the generation of Expert Centres, as public-private partnerships to support innovation and sustainability.

  • Project partners (BBMRI.at partners underlined): Medical University of Graz, Fundacio Centre de Regulacio Genomica, Commissariat a L'Energie Atomique et aux Energies Alternatives, Christian-Albrechts-Universität zu Kiel, Max Delbrueck Centrum für Molekulare Medizin in der Helmholtz-Gesellschaft, Katholieke Universiteit Leuven, Stockholms Universitet, Uppsala Universitet, Kungliga Tekniska Hoegskolan, Deutsches Krebsforschungszentrum Heidelberg, Institut National de la Sante et de la Recherche Medicale, European Molecular Biology Laboratory, Tartu Ulikool, Charite – Universitätsmedizin Berlin, LGC Limited, Qiagen GmbH
  • Web: www.easi-genomics.eu

 

 

HDHL-INTIMIC

Knowledge Platform on Food, Diet, Intestinal Microbiomics and Human Health

 

Over 2 billion people in this world are overweight and the associated costs are 1.2 trillion dollar per year. At the same time, the population in many countries is ageing, which increases the incidence of malnutrition. This leads to underweight and micro deficiencies. lf no action is taken, diet-related diseases are expected to increase rapidly in the next decade, stretching health systems to the breaking point. In the JPI HDHL, 20 countries from within and outside of Europe are working on a programmed approach to align national R&I strategies and to fund new research, in order to facilitate true understanding of the relationship between diet, physical activity and health.

 

HDHL-INTIMIC (INtesTInal MICrobiomics) aims to coordinate national and regional programmes in the area of diet, intestinal microbiomics and health as well as nutrition and health in general, thereby contributing to the implementation of JPI HDHL objectives.

 

  • Topic: ‘A Healthy Diet for a Healthy Life'
  • Type of action: 
  • Funded by: Bundesministerium für Bildung, Wissenschaft und Forschung
  • Start/end: 2019-2022
  • Grant agreement number: 
  • Total/max. grant by consortium:  
  • Benefit/tasks for BBMRI.at partner: Medical University of Graz and Medical University of Vienna funded: They jointly manage work package 5, 'Networking and training', which organizes internal and external communication, one of the central tasks of the project.
  • Project partners (BBMRI.at partners underlined):Medical University of Graz; Karl-Franzens University Graz, Medical University of Vienna, Sigmund-Freud Private University Vienna, University of Veterinary Medicine and 42 other European partners.
  • Web: www.healthydietforhealthylife.eu/index.php/era-net/hdhl-intimic

 

 

ERINHA-Advance

Advancing European Research Infrastructure on Highly Pathogenic Agents

 

 

High-risk pathogens are of increasing relevance as triggers of dangerous infectious diseases and pandemics.

ERINHA is a pan-European distributed Research Infrastructure dedicated to the study of high-consequence emerging and re-emerging pathogens. It connects high security (BSL-4 and BSL3) facilities with longstanding experience of research in the field of highly infectious diseases. The over-arching goal of ERINHA is to provide capacities to conduct projects which are broad in scope, ambition and require a range of capabilities that no single facility or even country can provide on its own. Such a coordinated approach is vital in a context marked by frequent globalization of infectious diseases with high risk for public health, society and economy. More at Cordis.Europe.eu

 

At Med Uni Graz the participation in ERINHA has enabled the establishment of a BSL-3 laboratory with the currently highest safety standard in Austria and thus created the prerequisites for numerous research projects relating to SARS-CoV-2.

 

  • Topic: H2020-INFRADEV-2018-1 Advancing European Research Infrastructure on Highly Pathogenic Agents
  • Type of action: RIA - Research and Innovation action
  • Funded by: EU Horizon 2020
  • Start/end: 2019-2021
  • Grant agreement number: 824061
  • Total/max. grant by consortium: € 3 746 804,14
  • Benefit/tasks for BBMRI.at partner: Medical University of Graz funded
  • Project partners (BBMRI.at partners underlined): Medical University of Graz, European Research Infrastructure on Highly Pathogenic Agents, Institut National de la Sante de la Recherche Medicale, Instituto Nacional de Saude Dr. Ricardo Jorge, Folkhalsomyndigheten, Nemzeti Nepegeszsegugyi Kozpont, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani-Instituto di Ricovere e Cura a Carattere Scientifico, INSERM Transfert SA, Karolinska Institutet, Katholieke Universiteit Leuven, Bernhard-Nocht-Institut für Tropenmedizin, ERASMUS Universitair Medisch Centrum Rotterdam
  • Web: www.erinha.eu/

 

 

 

CONCEPTION

 

 

ConcePTION will build an ecosystem for better monitoring and communicating of medication safety in pregnancy and lactation: validated and regulatory endorsed workflows for fast, optimised evidence generation. More at Cordis.Europe.eu

 

  • Topic:  IMI2-2017-13-09, ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now
  • Type of action:  IMI2-RIA Research and Innovation action
  • Funded by: EU – Horizon 2020
  • Start/end: 2019 -2024
  • Grant agreement number: 821520
  • Total/max. grant by consortium: €15,299,991.00
  • Benefit/tasks for BBMRI.at partner: Medical University of Graz funded
  • Project partners (BBMRI.at partners underlined): Medical University of Graz (linked 3rd party to BBMRI-ERIC), others
  • Web:  www.imi-conception.eu

 

 

EJP RD

European Joint Programme on Rare Diseases

 

 

The European Joint Programme on Rare Diseases brings over 130 institutions from 35 countries to create a comprehensive, sustainable ecosystem allowing a virtuous circle between research, care and medical innovation.

Its aims are to improve the integration, the efficacy, the production and the social impact of research on RD through the development, demonstration and promotion of Europe/world-wide sharing of research and clinical data, materials, processes, knowledge and know-how; and to implement and further develop an efficient model of financial support for all types of research on RD (fundamental, clinical, epidemiological, social, economic, health service) coupled with accelerated exploitation of research results for benefit of patients. More at Cordis.Europe.eu

 

  • Topic:  SC1-BHC-04-2018, Rare Disease European Joint Programme Cofund
  • Type of action:  CSA - Coordination and support action
  • Funded by: EU Horizon 2020
  • Start/end: 2019-2023
  • Grant agreement number:  825575
  • Total/max. grant by consortium: €55,582,724.77
  • Benefit/tasks for BBMRI.at partner: Medical University of Graz funded
  • Project partners (BBMRI.at partners underlined): Medical University of Graz (linked 3rd party to BBMRI-ERIC), others
  • Web:   www.ejprarediseases.org

 

 

 

EOSC-LIFE

 

 

EOSC-Life brings together the 13 Biological and Medical ESFRI research infrastructures (BMS RIs) to create an open collaborative space for digital biology. EOSC-Life will publish FAIR data and a catalogue of services for the management, storage and reuse of data in the European Open Science Cloud (EOSC). The project also implements interdisciplinary workflows for life scientists. Via open calls, researchers and project consortia can work with the European Life Science Research Infrastructures and their technical experts to bring their data, tools and workflows into the cloud. Finally, EOSC-Life addresses policies for human research data under GDPR with standards for data provenance and reproducibility, opening a route to set up registries for clinical trial data. More at Cordis.Europe.eu

 

  • Topic:  INFRAEOSC-04-2018; Connecting ESFRI infrastructures through Cluster projects
  • Type of action:  RIA - Research and Innovation action
  • Funded by: EU Horizon 2020
  • Start/end: 2019-2023
  • Grant agreement number: 824087
  • Total/max. grant by consortium: € 26 145 996,25
  • Benefit/tasks for BBMRI.at partner: Medical University of Graz funded
  • Project partners (BBMRI.at partners underlined): Medical University of Graz (linked 3rd party to BBMRI-ERIC), others
  • Web:   www.eosc-life.eu  

 

 

SPIDIA4P

SPIDIA for Personalized Medicine – Standardisation of generic Pre-analytical procedures for Invitro DIAgnostics for Personalized Medicine

 

 

Molecular in vitro diagnostics and biomedical research have allowed great progress in personalised medicine but further progress is limited by insufficient guidelines for pre-analytical workflow steps (sample collection, preservation, etc.) as well as by insufficient quality assurance of diagnostic practice. This allows using compromised patients' samples with post collection changes in cellular and extra-cellular biomolecules' profiles thus often making diagnostic test results unreliable or even impossible.

 

Thus, SPIDA4P aims to generate and implement a comprehensive portfolio of 22 pan-European pre-analytical CEN/TS and ISO/IS, addressing the important pre-analytical workflows applied to personalized medicine. More at Cordis.Europe.eu

 

  • Topic:  SC1-HCO-02-2016
  • Type of action:  CSA - Coordination and support action
  • Funded by: EU Horizon 2020
  • Start/end: 2017-2021
  • Grant agreement number: 733112
  • Total/max. grant by consortium:  € 1 999 972,50
  • Benefit/tasks for BBMRI.at partner:  Medical University of Graz funded
    • Leader of Work Package 3 "Implementation and Dissemination of Standards & External Quality Assurance Schemes" with 21 tasks

    • Leader of the development of ISO 20166-4:2021 Molecular in vitro diagnostic examinations — Specifications for preexamination processes for formalin-fixed and paraffin-embedded (FFPE) tissue — Part 4: In situ detection techniques

    • Leader of the development CEN/TS 17626:2021 Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for human specimen - Isolated microbiome DNA

  • Project partners (BBMRI.at partners underlined): QIAGEN GmbH, LGC Limited, Technische Universitaet Muenchen, DIN Deutsches Institut fuer Normung E.V. (on behalf of CEN), Preanalytix Gmbh, Inivata Ltd, Cambridge Protein Arrays Ltd. TATAA Biocenter Ab, Universita degli Studi Di Firenze, Consorzio Interuniversitario Risonanze Magnetiche di Metallo Proteine, Universita Degli Studi Di Trieste, Universita Degli Studi Di Torino, Biobank & Biomolecular Resources Research Infrastructure), Integrated Biobank of Luxembourg (Luxembourg Institute of Health), Medical University of Graz, Institut National de la Sante et de la Recherche Medicale, Erasmus Universitair Medisch Centrum Rotterdam, Fundacio Centre De Regulacio Genomica, Fondazione IRCCS Istituto Nazionale dei Tumori,
  • Web:  www.spidia.eu

 

 

 

 

Codex4SMEs 

Companion Diagnostics expedited for SMEs

The Interreg project Codex4SMEs (Companion diagnostics expedited for small and medium-sized businesses) project plans to improve healthcare by enhanced adoption of Personalized Medicine in North-West Europe. The objective is to establish a network, which supports SMEs along the value chain of Companion diagnostics (Cdx) development.

  • Topic: IMI2-2019-18-01 – Central repository of digital pathology slides to support the development of artificial intelligence tools
  • Funded by: EU Interreg-Nord-West-Europa-Programms (INTERREG NWE)

  • Type of action: Interreg is part of the structural and investment policy of the European Union, which supports cross-border cooperation between regions and cities
  • Start/end: 2017-2023
  • Grant agreement number: 
  • Total/max. grant by consortium:  €4,180,000 (from EU €2,500,000)
  • Benefit/tasks for BBMRI.at partner: Medical University of Graz/Biobank Graz funded
  • Project partners (BBMRI.at partners underlined): Medical University of Graz – Biobank Graz, BOM Holding BV, NL; Innovation and Management Centre Limited T/A WestBIC, IE; InnovationQuarter, NL; Medicen Paris Region, FR; Integrated BioBank of Luxembourg, LU; EIT Health Germany GmbH, DE; European Research Infrastructure for Translational Medicine, NL; FlandersBio, BE
  • Web: www.nweurope.eu/projects/project-search/codex4smes-companion-diagnostics-expedited-for-smes/

 

HRSM "Inter-University Infrastructure for Digital Pathology"

 

Histological sections contain detailed information about disease processes, which is essential for medical research and diagnosis of diseases. Advances in the digitization of histological sections and machine learning make it possible to analyze digital information from complex images of tissue sections. For this purpose, a national inter-university digital pathology infrastructure is to be set up, which will involve the medical universities in Graz, Vienna and Innsbruck as well as the University of Veterinary Medicine Vienna.

Topic: „Digitale Transformation in der Hochschulbildung": Gemeinsame Plattform der Medizinischen Universitäten Österreichs für interaktive Bild-basierte Lehre

Type of action: 

Funded by: Bundesministerium für Bildung, Wissenschaft und Forschung, Hochschulraumstrukturmittel (HRSM)

Start/end: 2017-2021

Grant agreement number: 

Total/max. grant by consortium: 

Benefit/tasks for BBMRI.at partner: Medical University of Graz funded

Project partners (BBMRI.at partners underlined): Medical University of Graz; Medical University of Vienna, Medical University of Innsbruck, University of Veterinary Medicine, Medical facultry of the Johannes Kepler University Linz

Web: --

 

 

ADOPT BBMRI-ERIC

implementAtion anD OPeration of the gateway for healTh into BBMRI-ERIC

 

 

"BBMRI-ERIC: the Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium, aims to establish, operate and develop a Pan-European distributed research infrastructure in order to facilitate the access to biological resources as well as facilities and to support high quality biomolecular and biomedical research.
The ADOPT BBMRI-ERIC proposal aims at boosting and accelerating implementation of BBMRI-ERIC and its services. Its main deliverables are designed to complete or launch the construction of key Common Services of the Research Infrastructure as required for ESFRI-projects ""under implementation"", reflecting the targets of the European Research Area (ERA). More at Cordis.Europe.eu

 

  • Topic:  H2020-INFRADEV-3-2015
  • Type of action:  RIA - Research and Innovation action
  • Funded by:  EU Horizon 2020
  • Start/end: 2015-2019
  • Grant agreement number: 676550
  • Total/max. grant by consortium: € 4 949 448,90
  • Benefit/tasks for BBMRI.at partner: Medical University of Graz funded
  • Project partners (BBMRI.at partners underlined): Medical University of Graz (linked 3rd party to BBMRI-ERIC), others
  • Web:   www.bbmri-eric.eu/scientific-collaboration/adopt-bbmri-eric

 

 

RD-CONNECT

An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research

 

Despite examples of excellent practice, rare disease (RD) research is still mainly fragmented by data and disease types. Individual efforts have little interoperability and almost no systematic connection between detailed clinical and genetic information, biomaterial availability or research/trial datasets.

 

By developing robust mechanisms and standards for linking and exploiting these data, RD-Connect will develop a critical mass for harmonisation and provide a strong impetus for a global "trial-ready" infrastructure ready to support the IRDiRC goals for diagnostics and therapies for RD in close collaboration with the successful A/B projects. It will build on and transform the current state-of-the-art across databases, registries, biobanks, bioinformatics, and ethical considerations to develop a quality-assured and comprehensive integrated hub/platform in which complete clinical profiles are combined with -omics data and sample availability for RD research. The integrated, user-friendly RD-Connect platform, built on efficient informatics concepts already implemented in international research infrastructures for large-scale data management, will provide access to federated databases/registries, biobank catalogues, harmonised -omics profiles, and cutting-edge bioinformatics tools for data analysis. All patient data types will be linked via the generation of a unique identifier ("RD-ID") developed jointly with the US NIH. The RD-Connect platform will be one of the primary enablers of progress in IRDiRC-funded research and will facilitate gene discovery, diagnosis and therapy development. RD-Connect has the RD field at its heart and brings together partners with a strong track record in RD research (gene discovery and development of innovative treatments), as well as committed IRDiRC funding partners and representatives of all major international RD initiatives (EU/US/AU/JP) spanning patient organisations, research and public health, to maximise impact to RD patients. More at Cordis.Europe.eu

 

  • Topic:  FP7 -HEALTH-2012-INNOVATION
  • Type of action:  SP1 Collaboration
  • Funded by: EU FP7-HEALTH
  • Start/end: 2012-2018
  • Grant agreement number: 305444
  • Total/max. grant by consortium: € 11 997 111
  • Benefit/tasks for BBMRI.at partner: Medical University of Graz funded
  • Project partners (BBMRI.at partners underlined):Medical University of Graz, many others
  • Web:   http://rd-connect.eu

 

 

CORBEL

Coordinated Research Infrastructures Building Enduring Life-science services

 

 

The social and economic challenges of ageing populations and chronic disease can only be met by translation of biomedical discoveries to new, innovative and cost effective treatments. The ESFRI Biological and Medical Research Infrastructures (BMS RI) underpin every step in this process; effectively joining scientific capabilities and shared services will transform the understanding of biological mechanisms and accelerate its translation into medical care. More at Cordis.Europe.eu

 

Topic: H2020 INFRADEV-4

Type of action: RIA - Research and Innovation action

Funded by: EU Horizon 2020

Start/end: 2015-2020

Grant agreement number: 654248

Total/max. grant by consortium: € 14 837 800

Benefit/tasks for BBMRI.at partner: Medical University of Graz funded

Project partners (BBMRI.at partners underlined): Medical University of Graz (linked 3rd party to BBMRI-ERIC), others

Web:   www.corbel-project.eu

 

 

BBMRI-LPC

Biobanking and Biomolecular Resources Research Infrastructure – Large Prospective Cohorts

 

 

In recent years, biomedical research has crossed international borders in large, collaborative studies showing the value of multidisciplinarity and scale advantage. This has yielded valuable insights and some led to new and better medicines and treatments for diseases. However, disease-focused studies provide less insight in the real disease onset, the relative disease burden in the population, and the actual comparability of selected patients. Large prospective cohort (LPC) studies following up initially healthy participants for years or decades are considered more reliable and different diseases can be studied. LPC studies require large numbers of subjects which are costly but particularly benefited from the advent of high throughput techniques providing opportunities for powerful study designs. This project unites the large study sets of the European Biobanking and Biomolecular Research Infrastructure (BBMRI) and the International Agency for Research on Cancer (IARC), thus achieving a worldwide unique scale of integration. More at Cordis.Europe.eu

 

  • Topic: INFRA-2012-1.1.9 BBMRI - Large Prospective Cohorts
  • Type of action:  CP-CSA-Infra - Combination of CP and CSA
  • Funded by: EU FP7-INFRASTRUCTURES
  • Start/end: 2013-2017
  • Grant agreement number: 313010
  • Total/max. grant by consortium: € 8 000 000
  • Benefit/tasks for BBMRI.at partner: Medical University of Graz 
  • Project partners (BBMRI.at partners underlined): Medical University of Graz funded
  • Web:   www.bbmri-eric.eu/news-events/bbmri-lpc-through-access-to-success/

B3Africa logo

B3AFRICA

Bridging Biobanking and Biomedical Research across Europe and Africa

 

 

B3Africa - Bridging Biobanking and Biomedical Research across Europe and Africa will dramatically improve and facilitate the development of better predictive, preventive and personalized healthcare worldwide. The rapidly evolving African biobanks are an invaluable resource: The African population has the greatest genomic diversity on the planet and represents an incredible resource of information to advance biomedical research. B3Africa aims to implement a cooperation platform and technical informatics framework for biobank integration between Africa and Europe. The collaboration harmonizes the ethical and legal framework, biobank data representation and bioinformatics pipelines for sharing data and knowledge among biobanks and allowing access for researchers from both continents. More at Cordis.Europe.eu

 

  • Topic: INFRASUPP-6-2014
  • Type of action: CSA - Coordination and support action
  • Funded by: EU – Horizon 2020
  • Start/end: 2015-2018
  • Grant agreement number: 654404
  • Total/max. grant by consortium: € 2 001 250
  • Benefit/tasks for BBMRI.at partner: Medical University of Graz funded
  • Project partners (BBMRI.at partners underlined): Medical University of Graz, others
  • Web:   www.b3africa.org 

Asset Publisher Asset Publisher

Sample quality management: News from SPIDIA4P

About the project, its partners and its work ... (Jan 2018)


DIGI-B-CUBE Ambassadors Network: Matchmaking Webinar

22 Oct 2020


SAVE-THE-DATE: Digital Pathology & Image Analysis Training School

At BBMRI.at Partner Med Uni Wien, 8-10 February 2021


State of the Art Lectures on NGS in Healthcare

- January 26th 2021, 13:00 – 14:50 CET


SPIDIA4P Newsletter

January 2021


Tablet against COVID-19 transmission

research at universities in Graz


Corona drug tests in Graz

at BSL-3 facility at BBMRI.at partner Med Uni Graz – April 2021


Precision Diagnostics Europe 2021

LAST CHANCE TO REGISTER until 15 May 2021


COVID-19 Nasal spray

...ORF TV report about research at BBMRI.at partner Med Uni Graz


BBMRI.at Partner Med Uni Graz collaborates with Google

Biobank samples help to fight cancer (Kleine Zeitung, 27 July 2021)


New pre-analytics ISO standards published

ISO 20166-4 FFPE tissue – in situ detection & ISO 23118 metabolomics in urine, blood, serum


SPIDIA4P

Newsletter August 2021


Researchers from Graz rely on nasal spray with banana protein

TV report on RTL (17 Aug 2021)